Variant position: 93 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 395 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human LKVIVNSLKNMINTFVPSGK IMQVVDEKLPGLLGNFPGPFE
Chimpanzee LKVIVNSLKNMINTFVPSGK IVQVVDEKLPGLLGNFPGPFE
Mouse LRILVNSITSLVNTFVPSGK LMKMVDQKLPGMIGSLPDPFG
Rat LRTLVNSISNLVNAFVPSGK IMQMVDEKLPGLIGSIPGPFG
Bovine LKVIVNSMKNIVNAFVPSGK IIHLVDQKLPGLLGNFPGPFE
Caenorhabditis elegans IADLIGVLINLITPWFPNA- -IDFVDDVFGDLAPKLAQPYR
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
22 – 142 Acid ceramidase subunit alpha
31 – 340 Interchain (between alpha and beta subunits)
73 – 101 Missing. In isoform 3.
80 – 80 L -> Q. No effect on autocatalytic processing, but loss of ceramidase activity, when associated with 165-Q--Q-167.
90 – 105
Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification of the first molecular lesion causing Farber disease.
Koch J.; Gaertner S.; Li C.M.; Quintern L.E.; Bernardo K.; Levran O.; Schnabel D.; Desnick R.J.; Schuchman E.H.; Sandhoff K.;
J. Biol. Chem. 271:33110-33115(1996)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); PARTIAL PROTEIN SEQUENCE; VARIANT FRBRL LYS-222; VARIANTS MET-72; VAL-93 AND ALA-246; GLYCOSYLATION; CATALYTIC ACTIVITY;
A new gene family predicted by a novel human heart cDNA.
Churchill J.R.; Wieland S.J.; Hoffman S.; Gallin E.K.; Murphy P.M.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANTS MET-72; VAL-93 AND ALA-246;
Human acid ceramidase gene: novel mutations in Farber disease.
Zhang Z.; Mandal A.K.; Mital A.; Popescu N.; Zimonjic D.; Moser A.; Moser H.; Mukherjee A.B.;
Mol. Genet. Metab. 70:301-309(2000)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS FRBRL HIS-22; ASP-23; VAL-138; LYS-222 AND ASP-320; VARIANTS MET-72; VAL-93 AND ALA-246;
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3); VARIANTS MET-72; VAL-93 AND ALA-246;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.